Sodium Gluconate
FDA-approved product (injectable, injection).
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 0 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBL- Anti-infective classification
- Neither a WHO ATC code nor an FDA pharmacologic class was found for it, so whether it is already an antimicrobial is not established. It needs review and is not counted as a repurposing candidate.
Repurposing investigation
No supported pathogen reaches ≥40% AI-predicted activity for Sodium Gluconate, so it is not among the repurposing candidates. Its predictions are shown below.
AI-predicted activity
AI prediction · nothing measured- MRSA10.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli23.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae11.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis18.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Sodium Gluconate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Micronutrient Sprinkles in a Daycare Center
NCT00967551 · start 2009-07
Registered record
- Registry ID
- NCT00967551
- Conditions
- Diarrhea; Respiratory Infection
- Interventions
- Micronutrient Sprinkles with zinc; Micronutrient sprinkles without zinc
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-07
- Completion
- 2012-07
- Enrolment
- 143
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiarrhea; Respiratory InfectionInterventionMicronutrient Sprinkles with zinc; Micronutrient sprinkles without zincPhasePhase 3Registry statusCompletedPhase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome
NCT01009502 · start 2009-07
Registered record
- Registry ID
- NCT01009502
- Conditions
- Myelodysplastic Syndromes
- Interventions
- sodium stibogluconate
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Terminated
- Start
- 2009-07
- Completion
- 2013-05
- Enrolment
- 1
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMyelodysplastic SyndromesInterventionsodium stibogluconatePhasePhase 1Registry statusTerminatedCombined Vitamins and Minerals Decrease Incidence of Upper Respiratory Tract Infections in Older Persons
NCT01484756 · start 2008-08
Registered record
- Registry ID
- NCT01484756
- Conditions
- Upper Respiratory Tract Infection
- Interventions
- daily multi micronutrient supplement; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-08
- Completion
- 2009-03
- Enrolment
- 270
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionUpper Respiratory Tract InfectionInterventiondaily multi micronutrient supplement; PlaceboPhasePhase 3Registry statusCompletedStudy of Bathing With Chlorhexidine Impregnated Cloths on Nosocomial Infections in the Pediatric Intensive Care Unit
NCT00549393 · start 2008-02
Registered record
- Registry ID
- NCT00549393
- Conditions
- Nosocomial Infections
- Interventions
- 2% Chlorhexidine gluconate cloth
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2008-02
- Completion
- 2012-06
- Enrolment
- 5,659
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNosocomial InfectionsIntervention2% Chlorhexidine gluconate clothPhasePhase 2 / Phase 3Registry statusCompletedSerum NGAL Levels in Hemodialysis (HD) Patients; Relation to Iron Status, HD and Intravenous (IV) Iron Administration
NCT00560976 · start 2005-12
Registered record
- Registry ID
- NCT00560976
- Conditions
- Renal Failure Chronic Requiring Hemodialysis
- Interventions
- Iron Saccharate (Venofer)
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2005-12
- Completion
- 2014-12
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRenal Failure Chronic Requiring HemodialysisInterventionIron Saccharate (Venofer)PhaseNot applicableRegistry statusUnknown